http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GT-200000102-A

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6951
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08L3-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C309-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-06
filingDate 2000-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90fe1c97baf029ef38384b4afa5e8918
publicationDate 2001-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber GT-200000102-A
titleOfInvention PHARMACEUTICAL COMPLEX.
abstract THE INVENTION REFERS TO AN ELECTRIPAN COMPLEX (A METHYLPIRROLIDINE) AND A BETA CYCLODEXTRINE SULFOBUTILETER [SHOWN IN FIGURE I, WHERE "R" = OH OO (CH2) 4) SO3 H], OR PHARMACEUTICALLY ACCEPTABLE SALES OF MIS PROCEDURES FOR THE PREPARATION OF SUCH COMPLEX, INCLUDING PHARMACEUTICAL FORMULATIONS AND USES OF THE SAME. ELETRIPTAN IS A 5HT RECEIVER AGONIST AND HAS BEEN HIGHLY EFFECTIVE FOR MIGRAINE TREATMENT, EMESIS HYPERTENSION, DEPRESSION, DRUG DEPENDENCY. IN ORDER TO ADMINISTER ELETRIPTAN, OR A SALT OF THE SAME, BY INTRANASAL ROUTE, IT IS DESIRABLE THAT THE FORMULATION DOES NOT PRODUCE IRRITATION IN THE NASAL MUCOSA, WITH THAT PURPOSE THE DEXTRINE COMPLEX HAS BEEN ADDED, ACHIEVING A GOOD BIODISPONIBILITY AND UNDERSTANDING FAST ACTION; THE FORMULATION ALSO INCLUDES INDISPENSABLE COMPONENTS AS ANTIOXIDANTS AND EXCIPIENTS.
priorityDate 1999-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID152743195
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419502955
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419526466
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID62698

Total number of triples: 36.